Brain and Central Nervous System Tumors Clinical Trial
Official title:
Prospective, Multi-Center Survey Study of Children and Adolescents With Craniopharyngioma
RATIONALE: Collecting information on how craniopharyngioma is diagnosed and treated may help
doctors predict a patient's response to treatment and help plan the best treatment. It may
also help identify the intermediate- and long-term effects of treatment.
PURPOSE: This clinical trial is collecting information on diagnosis, treatment, and quality
of life of young patients who are undergoing surgery for craniopharyngioma.
OBJECTIVES:
Primary
- Identify all applied therapy strategies in pediatric patients with craniopharyngioma.
- Correlate relapse status with different therapy strategies/modality in these patients.
- Determine the health status (i.e., ophthalmologic, neuropediatric, and endocrine
findings) and the health-related quality of life of these patients after treatment.
Secondary
- Determine the incidence of craniopharyngioma in pediatric patients.
- Identify quality control measures for diagnosis and therapy in these patients.
- Improve long-term care through a standardized follow-up program in these patients.
- Determine the efficacy of endocrine substitution for postoperative hypopituitarism in
these patients.
- Identify risk factors for developing obesity and correlate the neurotransmitter
concentration of leptin and neuropeptide Y in cerebral spinal fluid, serum, and
craniopharyngioma cystic fluid with the likelihood of developing obesity in these
patients.
- Determine the incidence and extent of eating disorders in these patients.
OUTLINE: This is a multicenter study.
Patients undergo neurologic, endocrine, and ophthalmologic tests and anthropometric
diagnostic measurements. Patients then undergo 1 of the following surgical procedures: total
resection; incomplete, subtotal, or partial resection; biopsy; or cyst pressure release.
Patients whose tumor relapses may undergo a second resection and/or radiotherapy.
Quality of life is assessed at baseline and then periodically thereafter.
After surgery, patients are followed periodically.
PROJECTED ACCRUAL: A total of 120 patients will be accrued for this study.
;
Masking: Open Label, Primary Purpose: Diagnostic
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT00006080 -
Fenretinide in Treating Patients With Recurrent Malignant Glioma
|
Phase 2 | |
Recruiting |
NCT00887146 -
Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma
|
Phase 3 | |
Suspended |
NCT00935090 -
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
|
N/A | |
Completed |
NCT00621686 -
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
|
Phase 2 | |
Terminated |
NCT00227032 -
Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme
|
Phase 1 | |
Completed |
NCT00112502 -
Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme
|
Phase 2 | |
Terminated |
NCT00243022 -
Dietary, Herbal and Alternative Medicine in Glioblastoma Multiforme
|
Phase 2 | |
Active, not recruiting |
NCT00087815 -
Hyperbaric Oxygen Therapy in Treating Patients With Radiation Necrosis of the Brain
|
N/A | |
Active, not recruiting |
NCT00278278 -
Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas
|
Phase 3 | |
Completed |
NCT00416819 -
Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Primary CNS Lymphoma
|
N/A | |
Completed |
NCT00052286 -
Modafinil in Treating Fatigue and Behavioral Change in Patients With Primary Brain Cancer
|
N/A | |
Completed |
NCT00006093 -
EMD 121974 in Treating Patients With Progressive or Recurrent Glioma
|
Phase 1/Phase 2 | |
Recruiting |
NCT00004129 -
Phosphorus 32 in Treating Patients With Glioblastoma Multiforme
|
Phase 1 | |
Completed |
NCT00004212 -
DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
Completed |
NCT00003417 -
Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme
|
Phase 1/Phase 2 | |
Completed |
NCT00003464 -
Temozolomide in Treating Adults With Newly Diagnosed Primary Malignant Glioblastoma Multiforme
|
Phase 2 | |
Completed |
NCT00003484 -
Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors
|
Phase 1 | |
Completed |
NCT00003173 -
High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors
|
Phase 2 | |
Completed |
NCT00003020 -
LMB-7 Immunotoxin in Treating Patients With Leptomeningeal Metastases
|
Phase 1 |